Mellitofixmet medicine diabeties type 2

ppt medical

1. By Ireny at 4:36 pm, Feb 11, 2021

2. In the co‐primary efficacy analyses, dapagliflozin did not reduce the risk of 3‐point MACE 2 (hazard ratio 0.93; 95% confidence interval 0.84–1.03; P = 0.17) ◦ MACE: major adverse cardiovascular events ▫ CV : cardiovascular ¥ DPP‐4 : dipeptidyl peptidase‐4 * GLP‐1 RA: glucagon‐like peptide‐1 receptor agonist ** SGLT‐2 : sodium–glucose co‐transporter type 2 ꝉ HF : heart failure Effect of new glucose lowering drugs on cardiovascular outcomes in placebo-controlled trials 2 ¥ ◦ ▫ ꝉ * **